Skip to main content

8th CeMM Karl Landsteiner Lecture by David M. Sabatini

The 8th CeMM Karl Landsteiner Lecture at the beautifully frescoed Festive Hall of the Austrian Academy of Sciences was delivered by Prof. David M. Sabatini of the Whitehead Institute for Biomedical Research of the Massachusetts Institute of Technology (MIT). More than 350 scientists and interested lay people from all walks of society attended the lecture, which was opened by CeMM’s Scientific Director Prof. Giulio Superti-Furga, who acknowledged Prof. Sabatini’s distinguished achievements and leading contribution to molecular biology. Gustav Ammerer, a Viennese biotech pioneer, research group leader at the Max F. Perutz Laboratories (MFPL) of…

Read more
Mutations of CALR have been discovered by CeMM recently in an estimated 15% of cases of myeloproliferative neoplasms (MPNs)

QIAGEN plans to develop kits for the detection of CALR mutations

Mutations of CALR have been discovered recently in an estimated 15% of cases of myeloproliferative neoplasms (MPNs - a group of blood disorders involving overproduction of blood cells) by the research team of Robert Kralovics at CeMM and collaboration partners at the Medical University of Vienna (NEJM doi: 10.1056/NEJMoa1311347). QIAGEN now licensed the technology from CeMM, and will develop a reliable diagnostic test for the CALR mutations offering each patient a clearer prognostic profile and guiding disease management. Development of a CALR diagnostic test will be highly complementary to QIAGEN’s kits for a key mutation of the Janus kinase…

Read more

Lange Nacht der Forschung (Long Night of Science) 2014

Lange Nacht der Forschung (Long Night of Science) 2014

(Vienna, 4 April 2014) Counting more than 135.000 visitors of all ages the ‘Lange Nacht der Forschung’ (Long Night of Science) 2014, a joint initiative of the Federal Ministry of Science, Research and Economy (BMWFW) and the Federal Ministry for Transport, Innovation and Technology (BMVIT), took place on Friday 4th April, at several locations throughout Austria. CeMM´s booth at the Aula der Wissenschaften in Vienna’s first district with about 3.200 visitors was a significant success. CeMM was represented with an information stand that also included a ‘hands-on’ science parcours with…

Read more

Entirely novel strategy to molecular anticancer therapy tricks malignant cells

New drug prevents tumour growth by inhibiting the nucleotide sanitizing enzyme MTH1

(Vienna, 2 April 2014) A ground-breaking study spearheaded by Scientific Director Giulio Superti-Furga at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences shows that fast-growing cancer cells are sensitive towards imbalances in the metabolism of nucleotides, the building blocks of DNA. This vulnerability can be exploited for a radically novel antitumour therapeutic approach. Not only did the researchers from Vienna, in a joint effort with colleagues from Oxford and Stockholm, identify the enzyme MTH1 as an Achilles heel of…

Read more

Herbert Gottweis

Herbert Gottweis, Professor at the University of Vienna and former Vice President of the Austrian Science Fund died prematurely on Monday, March 31, at the age of 56. We express our deepest condolences to his family and colleagues. We thank Herbert Gottweis for his professional and collegial support, and the great conversations we were privileged to hold on policy studies, the understanding of biomedical and healthcare transformation, and creativity in science. We will always remember his participation at the CeMM Retreat in 2012.

Read more

Empathy and Evidence – The Scientific Foundations of Palliative Medicine

Prof. Gian Domenico Borasio, M.D, Centre Hospitalier Universitaire Vaudois and University of Lausanne, gave the 3rd SMART lecture, on March 28th, 2014 at CeMM. Numerous scientists, clinicians and interested lay people witnessed a fascinating and thought-provoking lecture on “Empathy and Evidence – The Scientific Foundations of Palliative Medicine” followed by a lively forum discussion. Dr. Borasio, who is a leader in the science and implementation of modern palliative medicine started his talk by acknowledging the pioneering work of Dame Cicely Saunders followed by a detailed discussion of fundamental questions and concepts of ‘quality of…

Read more

Austria needs Science and Science needs Public Funding

Austrian research and universities need to be put on a solid financial basis!
Please sign and invite your colleagues to join:

www.wissenschaft-ist-zukunft.at

Read more

Austrodrugs Speed-Dating links the community

On March 7th 2014 more than 90 researchers interested in using and developing small molecules as biological probes and potential new drugs met at CeMM for the 4th Austrodrugs meeting organized by Stefan Kubicek and Giulio Superti-Furga. In a “scientific speed dating” 19 chemical biologists from academia and industry gave short 10-minute presentations. The well-balanced mix of speakers from different scientific backgrounds covered topics such as drug discovery, using and developing chemical probes to understand the biology of diseases, as well as virtual screening and modeling as a means of revealing drug interactions and drug targets. The…

Read more
f.l.t.r.: Giulio Superti-Furga, Arnold Pollak, Wolfgang Schütz, Kaan Boztug, Georg Stingl, Hubert Pehamberger, Robert Loewe, Peter Heil

CeRUD Opening Symposium

On February 28, 2014 the opening symposium of the Vienna Center for Rare and Undiagnosed Diseases (CeRUD) took place at the Jugendstil lecture hall of the Medical University of Vienna under the auspices of the Rector of the Medical University of Vienna, Wolfgang Schütz and the founding members, Arnold Pollak, Head of the University Hospital for Paediatrics and Adolescent Medicine, Hubert Pehamberger, Head of the University Hospital for Dermatology, Georg Stingl, Head the Clinical Department of Immunodermatology and Infectious Skin Diseases, and Giulio Superti-Furga, Scientific Director of the CeMM Research Center for Molecular Medicine of the…

Read more
Senior Author Robert Kralovics, first author Thorsten Klampfl

Discovery at CeMM and the Medical University of Vienna brings hope to millions of Myeloproliferative neoplasms patients

Klampfl T, et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. DOI: 10.1056/NEJMoa1311347

A newly identified mutation fills the gap in the molecular pathogenesis of MPN and brings hope to many MPN patients: To date a recently identified mutation in the gene called Janus kinase 2 (JAK2) MPN could be held responsible for MPN in 3/4 of the patients. The remaining patients however did not benefit from this discovery as their MPN was not caused by JAK2 mutations. The research group of Robert Kralovics at CeMM in collaboration with Heinz Gisslinger´s group at the Medical University of Vienna now succeeded in the discovery of…

Read more